Toll Manufacturing Supplements

Toll manufacturing is the brand-supplies-materials variant of supplement contract manufacturing. The brand owner purchases (and typically qualifies and tests) all components, ships them to the toll manufacturer, and pays only for the conversion service — blending, encapsulation, tableting, filling, packaging, and final QC release. The toll manufacturer's role is reduced to providing facility, equipment, personnel, MMR, BPR, QC unit operations, and final-product release; sourcing and qualifying components is the brand's responsibility.

• Proprietary or premium ingredients — brand owns supplier relationship for clinical-strain probiotic, branded botanical extract, single-source mineral, or trade-secret raw material. Brand does not want CM to know supplier identity or pricing.
• Supplier-of-record control — brand maintains direct supplier-qualification programme, COA review, audit cycle. Brand can switch CM without re-qualifying ingredient supply chain.
• Cost arbitrage — brand sourcing at scale across multiple SKUs may achieve better component pricing than CM sourcing for one SKU.
• Speed to market — brand may already have qualified supplier relationships from prior CM or in-house production; eliminates CM's re-qualification cycle.
• Multi-CM strategy — brand uses one supplier base across multiple CMs (different geographies, capacity overflow, redundancy); toll model is the only way this works without re-qualifying components per CM.
• Formulation IP protection — brand provides pre-blended or partially-processed proprietary intermediate; CM only completes final dosage form. Trade-secret formulation never disclosed.

The default quality-agreement template for full-service CM assumes the manufacturer owns component qualification. Toll model must explicitly re-allocate:

Operational mechanics that distinguish toll from full-service CM:

• Title — brand retains title to components throughout (toll manufacturer never owns them). Components on CM site are brand inventory; CM holds them in trust under bailment.
• Risk of loss — typically allocated per quality agreement; commonly brand bears risk until acceptance at CM dock, CM bears risk after (with insurance to cover bailed inventory).
• Storage segregation — CM must physically segregate brand-owned components from CM-owned and other-brand-owned components. Most CMs use dedicated cages or labelled bins.
• Inventory reporting — CM provides periodic inventory reports to brand (typically monthly); reconciliation against brand records.
• Yield variance — toll-manufacturing contracts typically include yield-loss tolerance (e.g. 2-3% acceptable loss in conversion); brand owns variance above tolerance.
• Scrap and rework — segregation extends to scrap and rework streams; brand-owned scrap is brand property and is returned or destroyed per brand instruction.

• CM skips identity test relying on brand COA — most common Warning-Letter pattern; toll arrangement does NOT exempt §111.75(a)(1)(i) verification.
• Quality agreement copies full-service CM template — fails to re-allocate component-qualification ownership; both parties assume the other is doing it; FDA finds neither.
• Brand changes component supplier without notifying CM — CM continues to use prior supplier identity-test method (which may not apply to new supplier). Discovered in audit.
• Inventory commingling — CM stores brand components co-mingled with own or other-brand inventory; chain-of-custody compromised.
• MMR change without bilateral review — brand changes formula and provides updated formula card; CM updates MMR but does not flag for bilateral re-approval per quality agreement.
• Complaint handoff gap — consumer complaint received by brand; brand routes to CM for investigation; CM lacks visibility to brand's full distribution and customer base; investigation incomplete.
• FDA inspection scope confusion — FDA inspects CM; asks about supplier qualification; CM says 'brand does that'; FDA cites CM for §111.12 because the CM as the manufacturer cannot delegate the regulatory obligation away even via quality agreement.

• Component ownership flag: per-component flag for 'brand-owned (bailed)' vs 'CM-owned'; surfaces in inventory, receipt, scrap, and reconciliation views.
• Supplier register split: 'Supplier qualified by' field = brand or CM; drives audit-evidence routing during FDA inspection prep.
• Identity-test enforcement: even when brand COA is attached and reviewed, V5 generates the §111.75(a)(1)(i) identity test work order on receipt and blocks release of the lot to production until identity is confirmed.
• Bailed-inventory storage: dedicated brand-owned locations; movement between brand-owned and CM-owned locations triggers transfer document + dual sign-off.
• Yield variance reporting: per-WO actual-vs-tolerance yield with cumulative monthly report to brand; over-tolerance variance flagged.
• Brand portal: brand sees real-time inventory levels of own bailed components, COA-on-file, identity-test status, current WOs in progress, and projected component depletion.
• Quality-agreement clause tracker: each clause of the executed quality agreement linked to the operational control point that enforces it; deviation from a clause triggers contractual-deviation workflow with bilateral notification.
• Scrap segregation: brand-owned scrap routed to dedicated scrap bin + reported to brand monthly; brand can elect return, destruction, or disposition.
• MMR bilateral approval: any change to MMR for a toll-manufactured product requires brand reviewer e-signature in addition to CM QA + reviewer signatures.
• Complaint routing: consumer complaints routed bilaterally — brand owns customer communication, CM owns manufacturing investigation; status visible to both.